

**Montanaro Global Innovation Fund**  
**Quarterly Commentary – Q4 2022****Market review**

As the global pandemic of Covid-19 eased, some commentators suggested an economic boom was on the cards. Freed from lockdown, the world was ready to party: *“Goodbye virus ... hello Roaring Twenties”* screamed one hopeful article in the *Financial Times*. You only had to look back a century to the boom that followed the 1918 pandemic (Spanish Flu) to see what would follow: a hedonistic decade of economic growth and stock market excess spurred by technological innovation (the car and the radio); *“the illicit thrill of Prohibition moonshine and the un-girdling of women”*<sup>1</sup>. London had its *“Bright Young Things”*, New York the Jazz Age of *The Great Gatsby*.

While economic growth initially rebounded faster from the impact of Covid than many had expected, 2022 brought surprises that derailed this trajectory. The first war in Europe since the Second World War brought with it rising oil prices and inflation unseen in a generation. The era of easy money came to an abrupt halt. The mood music changed. It was as brutal a start to a year as we can remember.

Our Funds recorded one of the worst months ever in relative terms in January 2022. The reason for this was a dramatic style rotation from Growth to Value, one of the fastest that we have witnessed in over 30 years of managing Small & MidCap portfolios. The swift change in sentiment was due to a burst of global inflation, which stoked fears of interest rate rises and disproportionately hurt long duration assets, notably Growth Small & MidCap equities.

The year did not get much better for Quality Growth managers as recessionary fears mounted. Exacerbated by the dreadful war in Ukraine, investors sought refuge in larger companies. The result was our worst year looking after investments for our clients since 2008 on an absolute basis and our worst relative year since the Eurozone crisis of 2013. Usually our Portfolios hold up well in market downturns due their high quality. Not so this time. The rotation out of SmallCap, Quality and Growth was a “perfect storm”. It is never nice to report such disappointing results and for this we are sorry.

---

<sup>1</sup> “The need for a damned good party”, *Financial Times*, 1 January 2021

## Portfolio

During the quarter, the NAV of the Sterling Accumulation B Share Class increased by 1.7%, an underperformance versus the MSCI World SMidCap Index of 1.5%.

**The strongest contribution** during the quarter came from **TransMedics**, a medical device company selling instruments and consumables to assist in organ transportation, which continued to outperform on the back of successful product launches in the US. **Axon**, a US developer of TASER and software products to help police and law enforcement agencies, outperformed on the completion of a convertible bond and upgraded status with GSA with the Axon software platform. **Esker**, the French provider of cloud software solutions to make their cash conversion cycle more efficient, rose after reporting solid Q3 numbers, including strong bookings growth.

**The weakest contribution** came from **Zscaler**, the global leader in cloud-based Zero Trust cyber security, which saw its shares derate despite excellent earnings growth, as interest rate hikes affected growth equity valuations. **Shockwave Medical**, the cardiology medical device company, also derated despite comfortably beating sell-side revenue expectations in Q3. **XPEL**, the protection film brand for automotive and other commercial applications, weakened on little news.

## Outlook

How to think about the months ahead from an investment perspective? Perhaps like the Aymara Tribe in South America, we should walk backwards into the future. In their culture, the most important feature of time is what we know: *“we can see the present and the past; they are laid out before us...anything we know or believe about the future is based on inference from what we have experienced in the present or the past...when making plans for the future, we should take much the same attitude as if we were walking backwards into unknown terrain”*<sup>2</sup>. As an investment house founded by an anthropologist, we find such a philosophy appealing.

With this in mind, what do we know and how can this inform our thinking? Many P/E valuations halved in 2022 and are back to 2016 levels or even 2008. Equity value is more attractive in our Quality Growth segment of the market than it has been for years. We also know that inflation dramatically rose last year but appears to have peaked last June. The US consumer price index declined in each of the last six months, while European inflation eased more than expected in November. This suggests that monetary policy may be having the desired effect. If this trend continues, central bankers may refrain from further tightening.

---

<sup>2</sup> *What We Owe The Future*, William Macaskill

We also know that economic growth has slowed, with some regions entering into recession. In such an environment, it is likely that the earnings of equity markets will decline this year. And here comes the nub of our outlook: in such an environment, the well capitalised Quality companies in which we invest should deliver *better* earnings growth than the wider market. As we walk (backwards) into the future, we can have confidence in the resilience of our companies and that, after a very difficult year, they are well placed to deliver attractive returns to our investors over the long term as they have in the past.

---

*The views expressed in this article are those of the author at the date of publication and not necessarily those of Montanaro Asset Management Ltd. The information contained in this document is intended for the use of professional and institutional investors only. It is for background purposes only, is not to be relied upon by any recipient, and is subject to material updating, revision and amendment and no representation or warranty, express or implied, is made, and no liability whatsoever is accepted in relation thereto. This memorandum does not constitute investment advice, offer, invitation, solicitation, or recommendation to issue, acquire, sell or arrange any transaction in any securities. References to the outlook for markets are intended simply to help investors with their thinking about markets and the multiple possible outcomes. Investors should always consult their advisers before investing. The information and opinions contained in this article are subject to change without notice.*

---